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Abstract 
Background: A specific T1-weighted magnetic resonance imaging (MRI) sequence has 
been shown to detect substantia nigra (SN) neuromelanin (NM) signal changes that 
accurately discriminate Parkinson’s disease (PD) patients from controls, even in early 
disease stages. However, it is unclear what happens to these SN changes in later disease 
stages and if they can be a marker of disease progression.  
Objective: to investigate the pattern of SN-NM area loss and contrast ratio (CR)  
intensity changes in late-stage PD (LSPD) compared to earlier disease stages.   
Methods: A comparative cross-sectional study was performed, analyzing SN-NM MRI 
signal in LSPD (Schwab and England Activities of Daily Living Scale score <50 or 
Hoehn Yahr Stage [HY] >3), comparing this group with de novo, 2-5 year PD and 
controls. SN-NM signal area and CR values for the internal and lateral SN regions were 
obtained with semi-automated methods.  
Results: 13 LSPD, 12 de novo patients with PD, 10 PD patients with a 2-5 year disease 
duration, and 10 controls were included. NM signal area was significantly decreased in 
LSPD compared to de novo PD (P-value = 0.005; sensitivity: 75%; specificity 92% and 
AUC: 0.86). In the lateral SN region, a decrease in the CR was detected in all PD 
groups compared to controls; despite not reaching statistical significance, a slight 
increment was observed comparing LSPD to 2-5 year PD. NM signal area significantly 
correlated with HY (R=-0.37; P<0.05) and Movement disorder Society Unified 
Parkinson’s Disease Rating Scale part II (MDS-UPDRS) (R=-0.4; P <0.05) while a 
weak correlation was found with MDS-UPDRS part III (R=-0.26; P: 0.1). 
Conclusion: SN area evaluated by NM-sensitive MRI may be a promising biomarker of 
nigral degeneration and disease progression in PD patients. 
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Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a selective 
loss of pigmented neurons in the substantia nigra (SN) pars compacta (SNc) and locus 
coeruleus (LC) and by the appearance of Lewy bodies [1, 2]. Approximately 60-70% of 
dopaminergic neurons of the SNc are lost before the onset of clinical PD symptoms and 
their degeneration progresses throughout the disease [3]. 
The degree of neuronal loss in the SNc is correlated to PD severity, which confirms the 
potential of SNc imaging for tracking disease progression [4]. 
The pronounced depigmentation of SNc neurons is related to the loss of neuromelanin 
(NM), which, in PD patients, occurs in the whole pars compacta region though 
preferentially affecting the ventrolateral part [5]. Over the last 10 years, new T1-
weighted magnetic resonance imaging (MRI) sequences have been shown to detect a 
significant reduction in the SN-NM signal in PD compared to healthy subjects; these 
sequences also enable the differential diagnosis with essential tremor [6]. Furthermore, 
a reduction of SN and LC contrast ratios (CR) has been reported in PD patients distinct 
from atypical parkinsonian syndromes [6-11]. These NM changes have a high 
diagnostic sensitivity and specificity for PD diagnosis, even in early clinical stages [8, 
12-14]. 
However, the relative ability of NM-sensitive MRI to mark disease progression and to 
detect potential differences in pathophysiological processes still remains unclear. 
Currently, very few studies have looked at longitudinal changes in the SN NM with 
MRI; inconsistent results have been reported, that could be related to differences in MR 
acquisition parameters and data analysis [12, 15-17]. Likewise, only a few studies have 
suggested a potential correlation of NM SNpc signal intensity loss (or CR) or NM-
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volume loss with disease severity, i.e. Hoehn and Yahr rating scale (HY) or Unified 
Parkinson’s Disease Rating Scale (UPDRS) scores [8, 11, 14, 16]. 
The purpose of this study was to investigate the pattern of SN-NM area loss and CR 
intensity changes in late-stage PD (LSPD) patients, compared to de novo PD patients 
and PD patients with a 2-5 year disease duration, and thereby evaluate NM changes 
throughout disease progression.  
 
Patients and Methods 
Patients  
We performed a comparative cross-sectional study that included 45 subjects: 13 LSPD, 
12 de novo PD patients, 10 PD patients with a 2-5 year disease duration, and 10 healthy 
subjects.  
Inclusion criteria for healthy subjects, de novo PD patients and patients with a 2-5 year 
disease duration has already been reported in a previous paper [12]. Patients were 
recruited from the Movement Disorders Unit of the University Hospital of Santa Maria, 
Lisbon. PD was defined according to the UK Brain Bank criteria [18] and diagnosis was 
made by a movement disorders specialist. LSPD was defined as PD patients with either 
a Schwab and England score (S&E) < 50 (MED ON) or a Hoehn &Yahr stage (HY) >3 
(MED ON) [19, 20]. 
PD patients were rated using the UPDRS, except for the LSPD group who were 
evaluated by means of the Movement Disorder Society (MDS) UPDRS[21], while 
MED ON. Conversion from the UPDRS-part II and UPDRS-part III to the MDS-
UPDRS part II and MDS-UPDRS part III respectively, was performed adopting the 
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algorithm proposed by Goetz and colleagues [22]. De novo PD patients were not on 
antiparkinsonian medication and they were all <6 months since the beginning of clinical 
symptoms.  L-dopa equivalent daily dose (LEDD) was calculated according to 
recognized standard conversions [23]. The Local Ethical Committee approved the study 
and all patients provided informed consent.   
 
Imaging Protocol 
A 3.0 T Phillips scanner (Phillips Achieva; Phillips Medical Systems, Best, Netherlands) 
was used to acquire all data. A T1 -weighted fast spin echo NM-sensitive pulse sequence 
was used as previously described by Sasaki and colleagues,[24] with a repetition 
time/effective echo time of 633/10 ms, echo train length of 3, 20 slices with 2.5 mm of 
thickness and intersection gaps of 0 mm, field of view of 220 mm, matrix size of 548  
474 (pixel size of 0.40  0.40 mm2) and an acquisition time of 8 min. Slices were set in 
an oblique axial plane perpendicular to the fourth ventricle floor and covering from the 
posterior commissure to the inferior border of the pons. Magnetization Prepared Rapid 
Acquisition Gradient Echo (MPRAGE) images were also acquired for volumetric 
analysis, with 0.740.741.0 mm3 resolution, TR/TE of 9.6/4.6 ms. In case of motion 
artefact, the sequence was repeated adjusting the slice positioning and reiterating to the patient 
on the importance of remaining still. 
 
Image Analysis 
The software OsiriX (OsiriX Lite version 8.0, Pixmeo, Geneva, Switzerland) was used 
to perform image analysis. A Gaussian filter (full width at half maximum of 0.8 mm) 
was applied to reduce image noise, prior to performing image segmentation using the 
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confidence region growing algorithm. As the high signal intensity SN was always 
visible in three slices, the middle slice, corresponding to the greatest SN volume was 
selected for segmentation.  
Two symmetrical seed points were manually defined on the most medial part of the 
high intensity area in the SN, and as close as possible to an imaginary straight line 
passing through the bottom of the interpeduncular cistern. The SN CR were assessed by 
positioning circular regions of interest (ROI), covering approximately 26 pixels, in the 
internal and lateral parts of both sides of the SN and in the lateral part of the crus 
cerebri, taken as a reference. The CR were calculated using the following equations:  
ܥܴ௜ோ =
ܵ ௜ܰோ
ܥܥோ
 
ܥܴ௜௅ =
ܵ ௜ܰ௅
ܥܥ௅
 
ܥܴ௟ோ =
ܵ ௟ܰோ
ܥܥோ
 
                     ܥܴ௟௅ =
ܵ ௟ܰ௟
ܥܥ௅
 
Where ܥܴ௜ோ,௜௅,௟ோ,௜௅ correspond to the CR of the internal right (ܴ݅), internal left (݅ܮ), lateral 
right (݈ܴ) and lateral left (݈ܮ) regions of the SN, respectively. ܵ ௜ܰோ,௜௅,௟ோ,௟௅ are the average 
values of the signal intensities within the ROIs positioned on the described regions of the 
SN, and ܥܥோ,௅ the average values of the signal intensities within the ROIs positioned on 
the right and left region of the crus cerebri, respectively (Figure 1).  
The midbrain and brainstem volumes were estimated using Freesurfer® for the automatic 
segmentation of the MPRAGE images. To account for inter-subject variability, the 
fraction of midbrain to brainstem volume (MBF) was calculated. 
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Statistical Analysis  
The Wilcoxon Ranked Test was used to test statistical differences between right and left 
NM area among subjects of each group. Kruskal-Wallis tests were employed with P-
values corrected for multiple comparisons using the Bonferroni method. Potential 
differences in the SN areas and in the clinical characteristics among the different groups 
were evaluated. The Wilcoxon signed-ranked test was performed to evaluate differences 
between the area and CR of both sides of the SN of each subject. 
Receiver operating characteristic curve (ROC) analyses were performed to determine 
the sensitivity, specificity, cut-off optimal values and the area under the curve (AUC) 
for distinguishing between the different PD groups. The Pearson product-moment 
correlation coefficient was used to evaluate the dependence between the MDS-UPDRS 
Part III score, MDS-UPDRS part II, LEDD, HY stage, age and the mean area of the SN 
and CRl/CRi results. Also, the dependence between the MBF and the SN areas was 
evaluated. 
Differences in the clinical characteristics were also assessed. The chi-squared test was 
performed to evaluate differences in the sex distribution among groups.  For comparison 
of the age between groups as well as for the MDS-UPDRS total score and MDS-
UPDRS Part III, the Kruskal-Wallis test was used.  A P value of 0.05 was considered 
significant.  
All analyses were performed with the R software (Version 3.3.1, The R Foundation for 
Statistical Computing, Vienna, Austria). 
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Results 
MRI was performed on all subjects, and the image quality allowed a clear identification 
of the high signal area in the SN region as well as a semi-automatic analysis of all NM-
MRI images.  
The demographic and clinical characteristics of all subjects are detailed in Table 1. 
LSPD patients had a median disease duration of 14 years [IQR: 9-17]. They were 
significantly older compared to controls and de novo PD patients and had a worse HY 
stage and MDS-UPDRS part II compared to the de novo and 2-5 year PD groups. MDS-
UPDRS part III scores of LSPD patients were worse compared to the de novo and 2-5 
year PD groups, but the difference was statistically significant only for 2-5 year PD 
patients (Table 1). 
We found no difference between the left and right NM areas (0.31 <P< 0.79) and so the 
mean right/left area value was used in all subsequent analysis.  
The median SN-NM area obtained for de novo PD patients, 2-5 year PD, LSPD groups 
and healthy subjects is detailed in Table 1.  
The median SN-NM area was markedly decreased in PD groups compared to controls 
(Figure 2) with a P value of 0.002 for de novo PD patients and a P value < 0.001 for 2-5 
year PD and LSPD groups (Table 1). The NM area of the LSPD group was significantly 
smaller when compared with the de novo group (P=0.005) but not when compared to 
the 2-5 year PD group (Table 1 and Figure 3).  
On ROC analyses, the sensitivity and specificity of the SN high signal area for 
discriminating the LSPD group from earlier PD groups were: a) 75% and 92%, 
respectively, with a cut-off value for the area set at 26.31 mm2 and an AUC of 0.86 if 
compared to de novo PD (Figure 3, Panel B); b) 70% and 62%, respectively, with a cut-
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off value for the area set at 19.29 mm2 and an AUC of 0.65 if compared to 2-5 year PD; 
(Figure 4, Panel C). The sensitivity and specificity for discriminating the 2–5 year PD 
group from the de novo group were 67% and 80%, respectively, with an area cut-off 
value of 27.16 mm2 and an AUC of 0.69 (Figure 3, Panel A). Finally the sensitivity and 
specificity for discriminating all PD patients from controls were 100% and 91%, 
respectively, with an area cut-off value of 33.02 mm2 and an AUC of 0.969 (Figure 4, 
Panel A). 
No differences were found among right versus left CR in both medial and lateral SN 
across all groups, except for the LSPD group (P <0.05). Thus, CR analysis was 
performed independently for left and right values. CR analysis for both right and left 
sides of the internal SN region showed no differences across all PD groups and controls. 
Concerning the lateral SN region, CR analysis showed a significant difference only for 
the left side between 2-5 year PD patients and controls (P<0.05).  
The median left and right CR results obtained for the internal and lateral SN region are 
detailed in Table 1. Across all groups no differences were found for the internal SN 
region (P =0.06), while CR in the lateral region was significantly different between 
controls and 2-5 year PD patients (P =0.008) (Figure 5). Although no other statistically 
significant differences were found, a tendency for CR decrease was observed with 
disease progression for early-intermediate stage groups (Figure 5). Contrary to this 
trend, an increment in CR was observed for the LSPD group if compared to the 2-5 year 
PD group (Figure 4).  
No statistically significant differences were found for the MBF across all groups (global 
P: 0.2) and no correlation was found between MBF and SN-NM area (R= 0.14; P = 
0.37).  
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No significant correlation was detected between SN-MN mean area and CR of the 
internal region (CRi) (R=0.33; P=0.054) and the CR of the lateral region (CRl) (R=0.3; 
P=0.08).  
Considering all PD groups, MDS-UPDRS part III showed no correlation with SN-NM 
area (R= - 0.26; P: 0.1). Negative moderate correlations were found between the SN-
NM area and the MDS-UPDRS part II (R= -0.4; P <0.05), LEDD (R= - 0.45; P <0.05) 
and HY (R= -0.37; P<0.05). No correlation was found between age and NM area 
values.  
A moderate correlation was found between age and CRl (R= - 0.42; P<0.05) and CRi 
(R=-0.36; P<0.05). No correlations were found between HY, MDS-UPDRS part II, 
MDS-UPDRS part III, LEDD and CRl or CRi. 
 
Discussion 
In the present study, we were able to identify a significant reduction in the NM-SN area 
compared to controls among several groups of PD patients belonging to different 
disease stages, i.e. from a very early stage up to LSPD. This is consistent with a 
tendency for NM depletion with disease progression. 
Our results also confirm the ability of NM-MRI related measures for differentiating PD 
patients from healthy controls with high accuracy, even in the early disease stages, as 
reported in previous studies. [8, 12, 13, 17] 
The main objective of our study was to investigate NM-MRI alterations in an LSPD 
sample, to see the NM changes with disease progression and its potential as a biomarker 
of disease progression in PD. The NM-SN area presented a tendency to decrease with 
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progressive disease stages, with statistical differences between de novo PD and LSPD 
patients. Furthermore, setting a cut-off value at 26.31 mm2, we found excellent 
sensitivity, specificity, and AUC values for differentiating de novo PD and LSPD 
patients (75%, 92% and 0.86, respectively). There are very few studies that have 
explored NM-area modifications in PD evaluating early, intermediate and advanced PD 
stages (from HY stage 1 to 4) and all included small sample sizes. These studies 
reported conflicting results, although the use of different imaging and analysis protocols 
may partly account for these differences [12, 15, 16, 25]. Indeed, in a previous report we 
found no differences in SN area or length when comparing de novo PD with 2-5 year 
PD patients.[12] A few other reports suggest a tendency for SN-NM area reduction with 
disease progression: Schwarz and colleagues observed a tendency for a decrease in NM 
area when comparing six PD patients with HY stages 1-1.5 with four PD patients with 
HY stages 2-3.[15] While Aquino and colleagues observed differences in NM area 
between twenty-two 3-5 year PD and twenty 6-10 year PD patients (HY stage <3).[25] 
Finally, a recent study by Matsuura and colleagues reported longitudinal changes in 
NM-SN area in a group of fourteen PD patients, suggesting a decline of approximately 
17.5%, after one year follow-up, concomitant with an aggravation of HY stage (from a 
range of 1-3 to 2-4).[16] However, to the best of our knowledge, this is the first study in 
which SN-NM area is specifically examined in a population of LSPD patients. Our 
findings are in agreement with the report of apparent disease stage- and duration-
dependent volume loss of the SN-NM-sensitive region as reported in a manual NM 
volume analysis, performed on PD patients presenting HY stages 1 to 5 [8]. An age-
related bias on NM area reduction among our sample of LSPD patients cannot be 
excluded, as those patients were statistically older when compared to de novo PD ones. 
However, a correlation with age was found only for CR values and not for NM area 
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values. In the current literature there is no consensus on the loss of pigmented neurons 
during normal aging [26-28]. Nevertheless, throughout a sensitive and specific 
biochemical quantification of NM, we know that in the SNc this pigment linearly 
increases with age from the 10th year up to the ninth decade of life. [26, 29]. Moreover 
in normal ageing the fallout of pigmented neurons has a very low rate, i.e. 4.7% per 
decade [3]. Taken as a whole, our findings on NM area reduction among LSPD patients 
do not seem to be significantly influenced by age and are more likely accounted for by a 
stage-dependent modification as opposed to an age-dependent factor. 
Though the MDS-UPDRS part III score showed no significant correlation with SN area 
depletion, we found a negative significant correlation of SN area with other indicators 
of disease severity, i.e. MDS-UPDRS part II and HY. Such a correlation is in agreement 
with our finding of NM area stage-dependent depletion, as suggested in a few other 
studies [14, 17]. The absence of a significant correlation between MDS-UPDRS part III 
and SN area depletion can be accounted for by the relatively high MDS-UPDRS-III 
scores of our de novo PD sample, probably linked to the medication-free condition of 
those patients and with the high frequency of tremor dominant type (11 over 12) [6]. 
Moreover, as showed in previous studies, the activities of daily life subscore, i.e. the 
MDS-UPDRS part II, may be a better biomarker of disease progression than other 
MDS-UPDRS sections [30-32]. 
To evaluate the possible impact of a midbrain volume reduction in PD patients which 
could have influenced NM measurements, the MBF was calculated for each group. As 
expected, the midbrain volume was similar between the groups and the calculated MBF 
showed no correlation with NM area depletion, confirming that individual midbrain 
volume does not explain the reduction of NM in PD [12]. 
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Concerning the CR assessment, although a statistically significant difference was 
observed when comparing PD patients to controls, and a there was a tendency for CR 
decrease with disease progression, a small and non-statistically significant increment in 
CR was observed for the LSPD group compared to the 2-5 year PD group. Even if 
LSPD patients had a clearly worse clinical condition and longer disease duration when 
compared to 2-5 year PD patients, they were taking a significantly higher levodopa 
dose. Dopamine and dopamine agonists in standard dosages do not markedly affect DaT 
binding. A recent study found a correlation of the CR of the SNc and LC with DAT 
binding values [33]. Interaction between NM-SN signal and dopaminergic therapy is 
currently unknown but its influence cannot be excluded.  
The pattern of pigmented neuron loss of the SN follows an opposite trend comparing 
PD patients with normal ageing to that observed for CR, with a greatest neuronal loss in 
PD (45% loss in the first decade), principally affecting the ventro-lateral part of the SN 
which is relatively spared in controls [3]. Accordingly, comparing healthy subjects with 
PD patients, we found a significant reduction of CR only in the lateral SN part. Those 
data suggest that CRl could be more appropriate than CRi in differentiating PD patients 
from healthy subjects. A few other studies on NM-CR in PD patients have reported 
heterogeneous results. Indeed, Ohtsuka and colleagues reported a NM-CR diminishing 
in the lateral-central part of SNc and LC in early (HY stage 1-2) and advanced (HY 
stage 3-5, during MED OFF) PD patients, compared to controls, but equally observed 
no difference between early and advanced patients, which is consistent to results from 
Schwartz and colleagues [15], however, no LEDDs were reported in either paper [17]. 
Conversely, Matsuura and colleagues reported a CR reduction during one-year follow-
up observation with a correlation between CR values and disease duration, in spite of a 
LEDD increasing from about 380 mg to 630 mg [16]. Moreover, CR values did not 
16 
 
show a significant correlation with indicators of disease severity (HY), further 
confirming that its alterations are not clearly coupled with disease progression [16] 
thereby suggesting that other confounding factors should be identified. Myoshi and 
colleagues found a stage-dependent CR reduction in the medial part of SNc, comparing 
1-2 HY PD patients with 3-5 HY ones [34]. Taken as a whole, even if CR of SNc 
should give a measure of the density of melanized neurons, its relationship with disease 
progression in PD remains to be clarified. Finally a greater signal attenuation on NM 
imaging has been found in the LC when compared to SNc among PD patients [7, 17], 
though no difference between early and advanced PD patients were found even in the 
CR of the LC [7, 17].  
A potential source of signal variability is the inhomogeneity in the B1 field, particularly 
relevant at 3.0T, which is known to affect image contrast. This effect should be 
accounted for in future studies, performing bias field correction prior to CR evaluation 
[35]. Future work should include assessing the variability in measured signal intensity 
and estimated NM-area associated to the acquisition and segmentation procedures. To 
assess the former, the acquisition procedure should be repeated after patient 
repositioning. 
Several neuroimaging techniques, such as [18F]fluorodopapositron emission 
tomography (PET), [11C]dihydrotetrabenazinePET, [123I]beta-carbomethoxy-3beta-(4-
iodophenyl) tropane single photon emission CT (DAT-SPECT), and 
[18F]fluorodeoxyglucose PET, have been proposed as markers for nigral abnormalities, 
disease progression or clinical characteristics for PD.[36, 37] For instance, longitudinal 
studies have shown an annual rate of reduction in striatal DAT uptake of 6–13% in PD 
patients [38, 39]. However, these examinations are invasive, expensive, and there is still 
uncertainty on whether there is an interaction between results and therapeutic 
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intervention outcomes. For this reason, these neuroimaging techniques are not 
commonly used for routine diagnosis or follow-up of PD patients. Moreover, a very 
recent study has shown a correlation between striatal DAT density, as measured by 
DAT-SPECT, and SN-NM volume loss [33]. On the other hand, transcranial ultrasound 
has also been shown to detect increased echogenicity in the SN in PD as an indirect 
measure of neuronal loss [40], but this technique is limited by the requirements of a 
good temporal bone window and its ability in tracking disease progression is still 
unclear. Recently the loss of the “swallow tail” in the dorsolateral SN as observed at 
high resolution 3T – SWI MRI has been proposed as an in vivo diagnostic biomarker 
for nigral degeneration in PD [14]. However even if such a radiological assessment 
yielded a high diagnostic accuracy (sensitivity 100%, specificity 95%), no longitudinal 
studies have investigated its modification with disease progression.  
Our study has several limitations namely the small number of patients in each group and 
the cross-sectional nature with no longitudinal follow-up. On the other hand, our results 
clearly show a significant NM signal area reduction in PD patients compared to controls 
and a tendency for an NM area decrease along with disease progression. These findings 
are consistent with previous reports and validate the consistency of our results. Due to 
the small number of patients we were not able to investigate the age-related effect on 
NM area reduction throughout other statistical techniques (stratification nor regression 
model). However, no correlation was found between age and area, suggesting a more 
probable role of disease stage on NM area reduction. NM-MRI has also several 
technical characteristics that have to be considered when evaluating the feasibility of 
performing related imaging studies. It requires a long acquisition time, and the images 
suffer from relatively low spatial resolution, in-plane signal inhomogeneity and not all 
image analysis processes are completely automated, although few operator-dependent 
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steps are required. Moreover, motion artifacts during image acquisition and partial 
volume effects may deteriorate the quantitative nature of the analyses. Nevertheless, we 
succeeded in performing MRI on all subjects without problems, obtaining good quality 
images and semi-automated analysis was possible for all patients. Finally there have 
been, so far, no reproducibility studies of NM-sensitive MRI. However, there have been 
up to now several studies using this specific sequence with different equipment and the 
obtained results are similar in terms of the identification of SN changes in PD 
patients[15, 25], which is strongly supporting sequence reliability. 
 
Conclusions 
In the present study, with semi-automated MRI measures, we detected a stage-
dependent progressive decrease in the SN-NM area of PD patients. A marked SN-NM 
area decrease occurred in parallel with other markers of disease severity. Our findings 
suggest that NM-sensitive MRI could be used as a potential biomarker for nigral 
degeneration and disease progression in PD patients. Furthermore, to the best of our 
knowledge, this is the first study that observed SN-NM area modifications in a sample 
of LSPD patients, allowing an assessment of the modifications of NM signal in very late 
disease stage. CR values, although showing a tendency for a decrease with disease 
progression, presented a slight, albeit not significant, increase in the LSPD group; its 
interaction with therapeutic intervention and its modifications with disease progression 
needs further investigation.  
Further longitudinal studies on a larger population and the use of consensus acquisition 
and analysis protocols are warranted in order to replicate our results, verifying if SN-
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NM area can measure PD patients’ progression and if it could be considered as a disease 
progression imaging biomarker in clinical trials.  
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TABLE 
 Healthy 
subjects 
De novo PD 2-5 year PD LSPD P value 
Number 
(female/male) 
10 (4/6) 12 (7/5)  9 (2/7) 13 (7/6) 0.3 
Age, yrs 60 [55-69.2] 62.5 [52.5 – 
73.7 ] 
66 [63.5 – 71.2] 78 [68.5-81.5] a, f: 1; b: 0.8; c: 
0.001; d: 0.003; e: 
0.08; 
HY NA 2 2 4 d - e: <0.001 
LEDD NA 0 480 [325-810] 1040 [725-1325] e <0.01  
MDS-UPDRS 
part II 
NA 6.2 [3.5 – 
10.6] 
10.1 [1.7 – 12.8] 36 [30-40.5] d-e: <0.001; f: 0.1 
MDS-UPDRS 
part III 
NA 32.3 [28.7 – 
47]  
24.5 [13.4 – 43.1] 51 [41-53.5] f: 1;  e: 0.02; d: 0.09; 
Area (〖mm
〗^2 ) 
 
 
40.63 
[33.03-
55.64] 
27.7 [17.13-
360.4] 
22.65 [8.64- 46.84] 18.68 [12.50 – 
26.47] 
a: 0.002; b, c 
<0.001; d: 0.005; e: 
1; f: 0.8; 
CR 
Internal 
region 
1.16 [1.11 – 
1.19]  
1.15 [1.09 – 
1.21]  
1.12 [1.05 – 1.16]  1.12 [1.09 – 
1.18] 
0.06 
CR 
Lateral 
region 
1.10 [1.02 – 
1.12] 
1.06 [0.10 – 
1.13] 
1.03 [0.99 – 1.08] 1.04 [0.10 – 1.1] b: 0.008; a,c:0.1; 
d,e,f: 1; 
Table 1. Demographic, clinical and neuromelanin assessment data of patients and 
controls. Values are presented as median [IQR: 25th - 75th percentile] if not otherwise 
specified. NA: not available; LEDD: levodopa equivalent daily dose. CR: contrast 
ration. HY: Hoehn and Yahr rating scale; MDS-UPDRS: Movement disorders society 
Unified Parkinson’s disease Rating Scale Comparisons: a) controls versus de novo PD; 
b) controls versus 2-5 yrs PD; c) controls versus LSPD; d) de novo PD versus LSPD; e) 
2-5 yrs versus LSPD; f: de novo PD versus 2-5 yrs PD. Statistical significant results are 
in bold characters. 
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FIGURES 
 
Figure 1. Representative CR assessment by means of circular regions of interest (ROIs) 
on an NM-sensitive T1-weighted MRI. CCr: crus cerebri right; CCL: crus cerebri left; 
SNiL: substantia nigra, left internal region; SNlL: substantia nigra, left lateral region; 
SNiR: substantia nigra, right internal region; SNlR: substantia nigra, right lateral region. 
 
 
Figure 2. Neuromelanin (NM) area selection on NM-sensitive MRI of the SN of a 
healthy control (a), a de novo PD patient (b) and a LSPD patient; 
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Figure 3. Median area values of the SN high intensity region on NM-sensitive MRI in 
de novo PD patients, 2-5 year PD patients, LSPD patients and controls.  
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Figure 4. Receiver Operator Characteristics (ROC) curves of the NM area for: a) 
differentiating between de novo PD versus 2-5 year PD patients (A); b) de novo PD 
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versus LSPD patients (B); c) 2-5 year PD versus LSPD patients (C); d) PD versus 
controls;  
 
 
Figure 5. CR values in in de novo PD patients, 2-5 year PD patients, LSPD patients and 
controls for the SN internal region (A) and lateral region (B).  
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